Table 3.
Univariate and Multivariate Analysis of Cancer-Specific Survival (CSS) Rates in Training Set
| Variables | No. of Patients | Univariate Analysis | Multivariate Analysis | |
|---|---|---|---|---|
| P value | HR (95% CI) | P value | ||
| Gender | <0.001 | |||
| Male | 5106 | Reference | ||
| Female | 3244 | – | 0.276 | |
| Age, years | <0.001 | |||
| <39 | 2911 | Reference | ||
| 39–44 | 1747 | 1.38 (1.14–1.68) | 0.001 | |
| >44 | 3692 | 1.20 (0.96–1.49) | 0.114 | |
| Race | <0.001 | |||
| White | 6626 | Reference | ||
| Black | 1033 | 1.39 (1.12–1.73) | 0.003 | |
| Others | 691 | 0.99 (0.74–1.33) | 0.932 | |
| Grade | <0.001 | |||
| Grade I | 1078 | Reference | ||
| Grade II | 3930 | 1.02 (0.61–1.70) | 0.939 | |
| Grade III | 1750 | 2.37 (1.45–3.88) | 0.001 | |
| Grade IV | 457 | 3.82 (2.30–6.33) | <0.001 | |
| Unknown | 1135 | 1.58 (0.93–2.69) | 0.091 | |
| AJCC stage | <0.001 | |||
| I | 5995 | Reference | ||
| II | 981 | 4.50 (2.52–8.03) | <0.001 | |
| III | 863 | 8.53 (5.19–14.02) | <0.001 | |
| IV | 511 | 20.37 (11.55–35.93) | <0.001 | |
| T stage | <0.001 | |||
| T1 | 6065 | Reference | ||
| T2 | 1097 | 1.41 (0.90–2.22) | 0.139 | |
| T3 | 1121 | 1.86 (1.25–2.76) | 0.002 | |
| T4 | 67 | 1.90 (1.16–3.10) | 0.010 | |
| N stage | <0.001 | |||
| N0 | 8010 | Reference | ||
| N1 | 184 | 1.88 (1.48–2.39) | <0.001 | |
| N2 | 156 | 1.82 (1.38–2.39) | <0.001 | |
| M stage | <0.001 | |||
| M0 | 7935 | Reference | ||
| M1 | 415 | 1.89 (1.33–2.67) | <0.001 | |
| Histology | <0.001 | |||
| CCRCC | 4998 | Reference | ||
| RCC-NOS | 2259 | 0.98 (0.81–1.19) | 0.855 | |
| PRCC | 736 | 0.84 (0.62–1.16) | 0.291 | |
| Others | 357 | 1.73 (1.34–2.23) | <0.001 | |
| SEER stage | <0.001 | |||
| Localized | 6976 | Reference | ||
| Regional | 950 | - | 0.056 | |
| Distant | 424 | - | 0.056 | |
| Chemotherapy | <0.001 | |||
| No/Unknown | 7982 | Reference | ||
| Yes | 368 | 1.48 (1.20–1.82) | <0.001 | |
| Radiotherapy | <0.001 | |||
| No/Unknown | 8202 | Reference | ||
| Yes | 148 | 1.46 (1.16–1.84) | 0.001 | |
Abbreviations: CSS, cancer-specific survival; HR, hazard ratio; CI, confidence intervals; AJCC, American Joint Committee on Cancer; SEER, Surveillance, Epidemiology, and End Results; RCC-NOS, renal cell carcinoma not otherwise specified; CCRCC, clear cell renal cell carcinoma; PRCC, papillary renal cell carcinoma.